Recent developments in nitric oxide-releasing biomaterials for biomedical applications

Tran

Regenerative Biomaterials

et al. 2022

The dual role of reactive oxygen and nitrogen species (RONS) in physiological and pathological processes in biological systems has been widely reported. It has been recently suggested that the regulation of RONS levels under physiological and pathological conditions is a potential therapy to promote health and treat diseases, respectively. Injectable hydrogels have been emerging as promising biomaterials for RONS-related biomedical applications owing to their excellent biocompatibility, 3-dimensional (3D) and extracellular matrix-mimicking structures, tunable properties, and easy functionalization. These hydrogels have been developed as advanced injectable platforms for locally generating or scavenging RONS, depending on the specific conditions of the target disease. In this review article, the design principles and mechanism by which RONS are generated/scavenged from hydrogels are outlined alongside a discussion of their in vitro and in vivo evaluations. Additionally, we highlight the advantages and recent developments of these injectable RONS-controlling hydrogels for regenerative medicines and tissue engineering applications.

Section: Injectable Rons-releasing Hydrogelsmentioning

confidence: 99%

Section: Injectable Rons-releasing Hydrogelsmentioning

confidence: 99%

Injectable reactive oxygen and nitrogen species-controlling hydrogels for tissue regeneration: current status and future perspectives

Tran

Regenerative Biomaterials

et al. 2022

“…In addition, two potential strategies to improve the effectiveness of existing NO therapy are also discussed, including the combination of NO-releasing platforms and either hydrogen sulfide (H 2 S)-based therapy or stem cell therapy. Recently, there have been several reviews on the delivery of NO for treating CVD [ 14 , 20 , 21 ]. Compared to these review works, this is the first comprehensive review on different levels of NO-releasing platforms, from NO donors or NO-related drugs to NO-releasing biomaterials to NO-based synergistic therapy for the treatment of CVD.…”

Section: Introductionmentioning

confidence: 99%

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Wang

et al. 2022

Pharmaceutics

Cardiovascular disease (CVD) is the first leading cause of death globally. Nitric oxide (NO) is an important signaling molecule that mediates diverse processes in the cardiovascular system, thereby providing a fundamental basis for NO-based therapy of CVD. At present, numerous prodrugs have been developed to release NO in vivo. However, the clinical application of these prodrugs still faces many problems, including the low payloads, burst release, and non-controlled delivery. To address these, various biomaterial-based platforms have been developed as the carriers to deliver NO to the targeted tissues in a controlled and sustained manner. This review aims to summarize recent developments of various therapeutic platforms, engineered to release NO for the treatment of CVD. In addition, two potential strategies to improve the effectiveness of existing NO therapy are also discussed, including the combination of NO-releasing platforms and either hydrogen sulfide-based therapy or stem cell therapy. Hopefully, some NO-releasing platforms may provide important therapeutic benefits for CVD.

“…However, as an active gas molecule, the biomedical application of NO is now mainly limited by the problems of storage, transportation, and release [ 12 ]. Recently, biomaterial-based scaffolds, including electrospun films, hydrogels, and metal nanoparticles, have been recruited in the NO delivery [ 13 , 14 ]. However, these scaffolds are still suffering the drawbacks such as low payload and burst release of NO [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

MOFs-Based Nitric Oxide Therapy for Tendon Regeneration

et al. 2020

Tendon regeneration is still a great challenge due to its avascular structure and low self-renewal capability. The nitric oxide (NO) therapy emerges as a promising treatment for inducing the regeneration of injured tendon by angiogenesis. Here, in this study, a system that NO-loaded metal–organic frameworks (MOFs) encapsulated in polycaprolactone (PCL)/gelatin (Gel) aligned coaxial scaffolds (NMPGA) is designed and prepared for tendon repair. In this system, NO is able to be released in vitro at a slow and stable average speed of 1.67 nM h−1 as long as 15 d without a burst release stage in the initial 48 h. Furthermore, NMPGA can not only improve the tubular formation capability of endothelial cells in vitro but also obviously increase the blood perfusion near the injured tendon in vivo, leading to accelerating the maturity of collagen and recovery of biomechanical strength of the regenerated tendon tissue. As a NO-loaded MOFs therapeutic system, NMPGA can promote tendon regeneration in a shorter healing period with better biomechanical properties in comparison with control group by angiogenesis. Therefore, this study not only provides a promising scaffold for tendon regeneration, but also paves a new way to develop a NO-based therapy for biomedical application in the future.